Drugs / HRS-2261
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05274516 | Mar → Oct 2022 | — | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05733533 | Mar 2023 → Mar 2024 | upper respiratory tract disorder | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-2261 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05274516 ↗ |
| Action | Inhibit | “HRS-2261, a novel selective P2X3 receptor antagonist” PMID 38198010 ↗ Jan 2024 |
| Route | Oral | “HRS-2261 oral tablet, oral, single dose.” NCT05274516 ↗ |